Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2017 ) > List of Articles

CARDIOVASCULAR THERAPEUTICS

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Ready to Target Atherosclerotic Cardiovascular Disease beyond Statins

Nidhi Mishra, Prabhash C Manoria

Citation Information : Mishra N, Manoria PC. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Ready to Target Atherosclerotic Cardiovascular Disease beyond Statins. Hypertens J 2017; 3 (3):147-153.

DOI: 10.5005/jp-journals-10043-0086

License: CC BY 3.0

Published Online: 00-09-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Manoria PC, Mishra N. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Ready to Target Atherosclerotic Cardiovascular Disease beyond Statins. Hypertens J 2017;3(3):147-153.


PDF Share
  1. LAI Expert Consensus Statement on Management of Dyslipidemia in Indians 2016. JAPI 2016 Mar;64:7-52.
  2. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology of the comprehensive type 2 diabetes management algorithm — 2017 executive summary. Endocr Pract 2017 Feb;23(2):207-227.
  3. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014 Jul;371(1):22-31.
  4. Variation in ANGPTL4 and risk of coronary heart disease: the atherosclerosis risk in communities study. Metabolism 2008 Nov;57(11):1591-1596.
  5. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 Apr;362(17):1563-1574.
  6. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011 Aug;217(2):492-498.
  7. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 Jun;372:2387-2397.
  8. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Expert Rev Clin Pharmacol 2016 Mar;9(5):655-663.
  9. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012 Nov;126(19):2283-2292.
  10. A two-step binding mode of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 2011 Feb;286(7):5464-5470.
  11. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 Jun;34(2):154-156.
  12. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res 2011 Apr;52(4):679-687.
  13. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012 Dec;23(6):511-517.
  14. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 May:376:1713-1722.
  15. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017 Apr;376:1430-1440.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.